Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SK10 is an investigational live biotherapeutic product (LBP) being developed by Zhiyi Biotechnology for the treatment of Crohn's Disease (CD). It is categorized as a biological product without prior human use, indicating that it utilizes a novel bacterial strain or microbial consortium not previously established in clinical practice. The drug is currently in the IND-enabling stage for submission to the U.S. Food and Drug Administration (FDA). As an LBP, SK10 is designed to address the underlying pathophysiology of Crohn's Disease by modulating the intestinal microbiota and host immune responses to reduce inflammation and restore gut homeostasis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SK10 (Zhiyi Pharmaceutics).